Bharat Biotech launches oral cholera vaccine Hillchol after positive phase 3 trial

Bharat Biotech unveiled Hillchol, a new single-strain oral cholera vaccine, developed with Hilleman Laboratories. Addressing the high global demand for cholera vaccines, the company can produce up to 200 million doses annually. Phase 3 trials validated its safety and effectiveness. The vaccine is administered orally to individuals over one year old.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/H3g9cIF
via IFTTT